Analytical Letters

Electrochemical biosensing has entered a new era driven by advances in nanomaterials, microfabrication, bio-recognition chemistry, and portable analytical systems. These developments are transforming clinical and biochemical diagnostics by enabling rapid, sensitive, and low-sample-volume detection of biomarkers relevant to infectious diseases, metabolic disorders, cancer, neurological conditions, and cardiovascular dysfunction. Modern biosensors now incorporate innovative electrode architectures, hybrid nanostructures, and integrated microfluidics that allow real-time monitoring with high specificity and minimal instrumentation. The combination of electrochemical transduction with wearable platforms, smartphone-based interfaces, and flexible materials opens promising pathways for point-of-care testing, decentralized healthcare, and personalized patient management. These innovations support early diagnosis, continuous health monitoring, and on-site biochemical analysis in both clinical and resource-limited environments. Despite this progress, major challenges remain before these technologies reach widespread clinical adoption. Ensuring device reproducibility, long-term stability, and calibration accuracy remains difficult due to variability in biological samples and material degradation. Translating laboratory prototypes into clinically validated devices requires robust standardization, rigorous biocompatibility testing, and clear regulatory pathways. Electrochemical interference from complex biological matrices often limits sensitivity and reliability, demanding new signal-processing strategies and electrode designs. Integrating biosensors into portable, connected systems raises questions about data integrity, patient privacy, and interoperability with healthcare networks. Addressing these challenges will define the next phase of innovation and determine how electrochemical biosensing can reshape diagnostic science and clinical decision-making.